Alumis Inc.(ALMS)

Pre23.370.000.00%04:01 EDT

23.37+0.64+2.82%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Why Is Alumis Stock Falling Monday?
  Benzinga_recent_news · 03-31
  Why Is Alumis Stock Falling Monday?
- Alumis falls -16.1%
  TIPRANKS · 03-31
  Alumis falls -16.1%
- Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS
  TIPRANKS · 03-30
  Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS
- Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
  TIPRANKS · 03-30
  Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
- Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says
  MT Newswires Live · 03-30
  Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says
- Oppenheimer Adjusts Alumis Price Target to $55 From $50, Maintains Outperform Rating
  MT Newswires Live · 03-30
  Oppenheimer Adjusts Alumis Price Target to $55 From $50, Maintains Outperform Rating
- Alumis Inc. : Oppenheimer Raises Target Price to $55 From $50
  THOMSON REUTERS · 03-30
  Alumis Inc. : Oppenheimer Raises Target Price to $55 From $50
- Alumis price target raised to $55 from $50 at Oppenheimer
  TIPRANKS · 03-30
  Alumis price target raised to $55 from $50 at Oppenheimer
- Alumis Is Maintained at Buy by HC Wainwright & Co.
  Dow Jones · 03-30
  Alumis Is Maintained at Buy by HC Wainwright & Co.
- Alumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission
  TIPRANKS · 03-30
  Alumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission
- Alumis envudeucitinib hits 68% PASI 90 at Week 24 in Phase 3 psoriasis trials
  Reuters · 03-30
  Alumis envudeucitinib hits 68% PASI 90 at Week 24 in Phase 3 psoriasis trials
- U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
  Reuters · 03-30
  U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
- Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib
  TIPRANKS · 03-29
  Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib
- Alumis says Phase 3 trials show envudeucitinib boosts psoriasis skin clearance by Week 24
  Reuters · 03-29
  Alumis says Phase 3 trials show envudeucitinib boosts psoriasis skin clearance by Week 24
- Alumis: New Data From Its Phase 3 Onward1 & Onward2 Clinical Trials Evaluating Envudeucitinib
  THOMSON REUTERS · 03-29
  Alumis: New Data From Its Phase 3 Onward1 & Onward2 Clinical Trials Evaluating Envudeucitinib
- Alumis: Envudeucitinib Showed Favorable Safety & Tolerability Profile Consistent With Phase 2 Program, No New Safety Signals Observed
  THOMSON REUTERS · 03-29
  Alumis: Envudeucitinib Showed Favorable Safety & Tolerability Profile Consistent With Phase 2 Program, No New Safety Signals Observed
- Alumis: Envudeucitinib Showed Robust Skin‑Clearance, Achieving High Thresholds of Clinical Responses From Week 16 to Week 24 in Both Trials
  THOMSON REUTERS · 03-29
  Alumis: Envudeucitinib Showed Robust Skin‑Clearance, Achieving High Thresholds of Clinical Responses From Week 16 to Week 24 in Both Trials
- Alumis: Continues to Evaluate Long-Term Efficacy & Safety of Envudeucitinib in Onward3 Long-Term Extension Trial
  THOMSON REUTERS · 03-29
  Alumis: Continues to Evaluate Long-Term Efficacy & Safety of Envudeucitinib in Onward3 Long-Term Extension Trial
- The Bull Case For Alumis (ALMS) Could Change Following Envudeucitinib Phase 3 Data And New Equity Plans - Learn Why
  Simply Wall St. · 03-22
  The Bull Case For Alumis (ALMS) Could Change Following Envudeucitinib Phase 3 Data And New Equity Plans - Learn Why
- Alumis (ALMS) Q4 Loss Of US$92.9 Million Tests Bullish Growth Narrative
  Simply Wall St. · 03-21
  Alumis (ALMS) Q4 Loss Of US$92.9 Million Tests Bullish Growth Narrative
Company Profile
Company Name
Alumis Inc.
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.alumis.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
- -
- 03-30
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 03-19
  Annual Report
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 03-19
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 01-30
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 01-09
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 01-06
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 01-02
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-11-13
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2025-11-13
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-09-03
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-08-16
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2025-08-13
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2025-08-13
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-08-04
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-06-30
  Major Issues Report
  Form 8-K/A - Current report: [Amend]
  Form 8-K/A - Current report: [Amend]

1D
5D
Day
Week
Month

Loading ...

High

23.89

Open

21.96

Volume%

0.56

Low

21.62

22.73

T/O Rate

1.85%

To The Moon

Alumis Inc.(ALMS)

Company Profile

Most Discussed